Management of Hypotension in Constrictive Pericarditis – Surgical Definitive Therapy and Contraindication of Midodrine

Definitive Surgical Treatment

Pericardiectomy is a Class I recommendation for chronic constrictive pericarditis in patients with persistent NYHA III–IV symptoms (European Society of Cardiology guideline). 1
The disease mechanism is mechanical restriction of ventricular filling by a rigid pericardium, which cannot be corrected by vasopressor or peripheral‑vasoconstrictor therapy (European Society of Cardiology). 1
Operative mortality for pericardiectomy ranges from 6 % to 12 %; it remains the only intervention that resolves the underlying mechanical obstruction (European Society of Cardiology). 1

Patients with end‑stage constrictive pericarditis derive little or no benefit from pericardiectomy and face markedly high operative risk (European Society of Cardiology). 1
Typical end‑stage features include severe cachexia, atrial fibrillation, low cardiac output (cardiac index < 1.2 L·m⁻²·min⁻¹), hypoalbuminemia, and impaired hepatic function (European Society of Cardiology). 1
Predictors of poor overall survival are prior thoracic radiation, reduced renal function, elevated pulmonary artery systolic pressure, abnormal left‑ventricular systolic function, low serum sodium, and advanced age (European Society of Cardiology). 1

Post‑operative low cardiac output should be managed with fluid replacement, catecholamine infusion, high‑dose digitalis, and, in severe cases, intra‑aortic balloon pump support (European Society of Cardiology guideline, 2004). 7

Midodrine activates α₁‑adrenergic receptors, producing arteriolar constriction and raising peripheral vascular resistance (pharmacologic mechanism). 4
In constrictive pericarditis, the resulting increase in afterload can further depress cardiac output by impeding left‑ventricular ejection (pharmacologic mismatch). 4
Elevated systemic vascular resistance from midodrine diverts blood into the pulmonary circulation, raising left‑ventricular filling pressures and worsening the hemodynamic burden of pericardial constriction (pathophysiologic concern). 4
Midodrine can trigger reflex bradycardia via parasympathetic (vagal) stimulation in response to the rise in blood pressure (pharmacologic effect). 4
The American College of Cardiology advises caution when using midodrine in patients with congestive heart failure, noting poor tolerability (ACC recommendation). 5
ACC guidance also recommends routine monitoring for bradycardia after midodrine initiation and discontinuation of the drug if significant bradycardia occurs (ACC recommendation). 5
In patients with constrictive pericarditis and a cardiac index < 1.2 L·m⁻²·min⁻¹, additional reflex bradycardia could be catastrophic (European Society of Cardiology). 1
Observational data in dialysis patients with cardiovascular disease show that midodrine use is associated with higher rates of cardiovascular events, all‑cause hospitalization, and mortality (real‑world evidence). 6

Do not “bridge” patients to pericardiectomy with midodrine; the drug’s afterload‑raising effect in a fixed‑output state may precipitate cardiovascular collapse (ACC & pharmacologic evidence). 5
Do not confuse the FDA‑approved orthostatic‑hypotension indication for midodrine with the low‑output hypotension of constrictive pericarditis, which has a fundamentally different pathophysiology (pharmacologic evidence). 4
When severe pre‑operative hypotension necessitates pharmacologic support, assess for end‑stage disease (cardiac index < 1.2 L·m⁻²·min⁻¹) because such patients have very poor surgical outcomes (European Society of Cardiology). 1
Refer patients to a centre with expertise in pericardial disease rather than attempting temporary medical therapy with inappropriate agents (European Society of Cardiology). 1